Oral Cancer Treatment Market Analysis

Application (Hospitals and Clinics, Research Organizations, Academic Institutes)

Hospitals and clinics segment is predicted to account for around 57.4% oral cancer treatment market share by 2037. The growth in this segment is driven by the availability of therapeutics, surgical interventions, and various therapies under one roof. This multidisciplinary approach of cancer care centers ensures comprehensive care of patients, encouraging more investment in this sector. The wide range of facilities including diagnosis, surgery, chemotherapy, and rehabilitation helps these institutions to establish steady growth. Rising oral cancer incidences have also inflated the frequency of hospital admissions for treatment, which shows the potential for this segment to grow higher.

Product Type (Squamous Cell Carcinoma, Verrucous Carcinoma, Minor Salivary Gland Carcinomas, Lymphomas)

Based on product type, the squamous cell carcinoma segment is predicted to generate remarkable revenues in the oral cancer treatment market. Innovation in immunotherapy has created new paradigms to offer better outcomes in advanced cases. Recently developed biologic agents and checkpoint inhibitors have opened new possibilities for recovering critical-stage patients. Increased survival rates due to advancements in early detection are also encouraging companies or research centers to develop new technologies such as liquid biopsies and enhance imaging techniques. For instance, in May 2o21, Viome launched an FDA-approved oral and throat cancer detection tool, based on its patented metatranscriptomics and AI platform. The screening test can detect OSCC and OPC by making saliva a liquid biopsy.

Our in-depth analysis of the market includes the following segments: